NCT01847664View on ClinicalTrials.gov

Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Uncomplicated Diverticulitis
Interventions
DRUG

Rifamycin SV-MMX® 400 mg b.i.d.

DRUG

Rifamycin SV-MMX® 600 mg t.i.d.

DRUG

Rifamycin SV-MMX® Placebo

Trial Locations (1)

51103

Evangelisches Krankenhaus Kalk, Cologne

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY